Œ¤‹†—̈æ‚Ö
•”–åˆê——‚Ö–ß‚é

Œ¤‹†‹ÆÑˆê——EResearch Achievements
i1997j


¶‰»ŠwuÀ‘æ‚P‹³Žº

Biochemistry 1




Šw p ˜_ •¶


Research Papers


1) Togashi S, Lim S, kwano H, Ito S,Isihara T, Okada Y, Nakano S, Kinosita T, Horie K, Episkopou V, Gottesman ME, Costantini F, Shimada K, Maeda S(1997) Serum amyioid P component enhances induction of murine amyloidosis. Lab InvestC77F525]531D

2) Takaoka Y, Tashiro F, Yi S, Maeda S, Shimada K, Takahashi K, Sakaki Y, Yamamura K(1997) Comparison of amyloid deposition in two lines of transgennic mouse that model familial amyloidotic polyneuropathy, type I. Transgenic ResearchC6F261]269D

3) Kohno K, Paiha JA Miyakawa MJMCIto S, Mabuchi T, Blaner WS, Iijima H, Tsukahara S, Episkopou V, Gottesman ME, Shimada K, Takahashi K, Yamamura K, Maeda S(1997) Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J PatholC150F1497]1508D

4) Kato G, Maeda S(1997) High]level expression of human c]Src can cause a spherical morphology without loss of anchorage]dependent growth of NIH3T3@cells. FEBS LettC411F317]321D

5) Yokota S, Okada Y(1997) Quantitative evaluation of procedures affecting immunogold staining in post embedding immunocytochemistry. Acta Histochem CytochemC30F497]504D


’P@s@–{


Books


1) ‘O“cGˆê˜Y(1997) transthyretin(TTR)DMolecular Medicine 34(—ÕŽž‘Š§†)DƒmƒbƒNƒAƒEƒgEƒf[ƒ^ƒuƒbƒN(–ìŒû@–΁C•½ˆä‹vŠÛ•Ò)D’†ŽR‘“XC“Œ‹žC505]506D


‘@@à


Review Articles


1) ‘O“cGˆê˜Y(1997) ‘ãŽÓˆÙíÇ‚ÌDNAf’f‚Æ”­Ç‹@˜D•a—‚ƗՏ°C15(9)F762]770C•¶Œõ“°D


Šw@‰ï@”­@•\


Oral Presentations


1) Maeda S, Gottesman ME, Saraiva MJM, Yamamura K, Shimada KFGene targeting in studies of function of transthyretin and pathogenesis of an inherited amyloidosis. ‘Û•ªŽqbó‘BŠwƒVƒ“ƒ|ƒWƒEƒ€(International Symposium on Moiecuiar Thyroidology)C1997CTokyo.

2) ˆÉ“¡’õ—mC‰Í–ì—T—mC•xŠ~TŽ¡C‰ª“c–F‰ÆC’†–ì^C–x]‹±“ñCÎŒ´“¾”ŽC“‡“c˜a“TC‘O“cGˆê˜YFAAƒAƒ~ƒƒCƒh’¾’…‚Ö‚ÌŒŒ´ƒAƒ~ƒƒCƒhP¬•ª(SAP)‚ÌŠÖ—^|–³SAPƒ}ƒEƒXŠ”‚ð—p‚¢‚½‰ðÍD‘æ70‰ñ“ú–{¶‰»Šw‘å‰ïC1997C‹à‘òD

3) ’|“c^•qC²“¡GŽ÷C”n•£@³Fy•êF1F0]ATP‡¬y‘fƒTƒuƒ†ƒjƒbƒg”ä‚ƈâ“`Žq‚̃Rƒs[”D‘æ70‰ñ“ú–{¶‰»Šw‰ï‘å‰ïC1997C‹à‘òD

4) ”n•£@³C’|“c^•qFy•êatp1]2 •ÏˆÙ‚ÌASC1(RAS2)‚É‚æ‚é—}ˆ³‚ƃ~ƒgƒRƒ“ƒhƒŠƒA‚ÌŒ`‘ԕω»D‘æ20‰ñ“ú–{•ªŽq¶•¨Šw‰ï”N‰ïC1997C‹ž“sD

5) ’|“c^•qC‘吼Ž“TC’†–ì@‘C‰œ‘‘ˆê˜YC”n•£³Fy•êF1F0]ATPaseƒTƒuƒ†ƒjƒbƒg‚̉»Šw—Ê”ä‚ƈâ“`Žq‚̃Rƒs[”D‘æ20‰ñ“ú–{•ªŽq¶•¨Šw‰ï”N‰ïC1997C‹ž“sD